Immunic and 4sc ag sign agreement regarding the settlement of royalty obligations for immunic's lead program, imu-838

New york and planegg-martinsried, germany, march 31, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4sc ag (fse prime standard: vsc), today announced the signing of an agreement under which immunic will settle its remaining obligation of a 4.4% royalty on net sales of selective oral dhodh inhibitor, imu-838, for $17.25 million. the transaction will be payable 50% in cash and 50% in shares of immunic's common stock.
IMUX Ratings Summary
IMUX Quant Ranking